<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GALANTAMINE HYDROBROMIDE</span><br/>(ga-lan'ta-meen)<br/><span class="topboxtradename">Razadyne, Razadyne ER<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">cholinergic (parasympathomimetic)</span>; <span class="classification">cholinesterase inhibitor</span>; <span class="classification">central acting</span><br/><b>Prototype: </b>Donezepril HCl<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>4 mg, 8 mg, 12 mg tablets; 8 mg, 16 mg, 24 mg extended release capsules; 4 mg/mL oral solution</p>
<h1><a name="action">Actions</a></h1>
<p>Competitive and reversible inhibitor of acetylcholinesterase which is the enzyme responsible for the hydrolysis (breakdown)
         of the neurotransmitter, acetylcholine.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Believed to increase concentration of the neurotransmitter, acetylcholine, in the CNS. If this mechanism is correct, the effect
         of drug will lessen as disease progresses and since fewer neurons stimulated by acetylcholine remain functionally intact.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of mild to moderate dementia of Alzheimer's type.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Vascular dementia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to galantamine. Not recommended with severe renal or hepatic impairment; pregnancy (category B), lactation,
         or in children.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Bradycardia, heart block or other cardiac conduction disorders; asthma, COPD; potential bladder outflow obstruction; a history
         of seizures or GI bleeding; concurrent use of drugs which slow the heart rate, drugs which may cause syncope, <small>NSAID</small>s, or neuromuscular blocking agents during anesthesia.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Alzheimer's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initiate with 4 mg b.i.d. times at least 4 wks, if tolerated may increase by 4 mg b.i.d. q4wk to target dose of 12 mg b.i.d.
               (816 mg b.i.d.)<br/><br/><span class="impairmenttitle">Hepatic Impairment</span><br/>Not recommended with severe hepatic impairment<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with meals (breakfast and dinner) to reduce the risk of nausea.</li>
<li>Extended release capsules should be swallowed whole and not crushed or chewed.</li>
<li>Make increases in dosage increments at four-week intervals.</li>
<li>If drug is interrupted for several days or more, restart at the lowest dose and gradually increase to the current dose.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Weight loss, fatigue, rhinitis, syncope. <span class="typehead">CNS:</span> Dizziness, headache, depression, insomnia, somnolence, tremor. <span class="typehead">CV:</span> Bradycardia, chest pain. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting,</span> diarrhea, anorexia, abdominal pain, dyspepsia, flatulence. <span class="typehead">Hematologic:</span> Anemia. <span class="typehead">Urogenital:</span> UTI, hematuria, incontinence. <span class="typehead">Other:</span> <span class="speceff-life">Increased mortality in patients with mild cognitive impairment.</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Additive effects with other <span class="classification">cholinesterase inhibitors</span> (e.g., <b>succinylcholine,</b>
<b>bethanecol</b>); <b>cimetidine,</b>
<b>erythromycin,</b>
<b>ketoconazole,</b>
<b>paroxetine</b> may increase levels and toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly and completely absorbed. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Distribution:</span> Mainly distributes to red blood cells. <span class="typehead">Metabolism:</span> Metabolized in liver primarily by CYP2D6 and CYP3A4. <span class="typehead">Elimination:</span> 95% excreted in urine. <span class="typehead">Half-Life:</span> 7 h (4.410 h). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiovascular status including baseline and periodic EKG and BP readings. Assess for postural hypotension.</li>
<li>Monitor respiratory status; report worsening of preexisting asthma or COPD.</li>
<li>Monitor I&amp;O rates and pattern for urinary incontinence or urinary retention.</li>
<li>Monitor appetite and food intake. Weigh weekly and report significant weight loss.</li>
<li>Lab tests: Baseline ALT/AST, BUN and creatinine; periodic blood glucose, alkaline phosphatase, urinalysis, stool for occult
            blood.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to a health care provider immediately: loss of weight, urinary retention, chest pain, palpitations,
            difficulty breathing, fainting, dark stools, blood in the urine.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>